바이오스펙테이터

by Sungmin Kim

Autotelic Bio announced that they have entered into an agreement with Clinigen Group, the British global pharmaceutical product and services company, January 14th, for the supply of IL-2 for investigational purposes.

Under this agreement, IL-2, currently marketed globally by Clinigen under the brand name, Proleukin® (Aldesleukin) will be supplied to Autotelic Bio for various clinical studies. Financial details were not disclosed.

Autotelic Bio is planning to proceed the local (Korea, Republic of) clinical phase 1b of ATB-301 (TGF-β2 inhibition & T-Cell activation; Immuno-Target Dual Action Onco-therapeutic) which is an investigational anticancer drug candidate with the potential for dual function of immune targets. Where TGF-β2 inhibitors weaken the immune avoidance mechanism of cancer cells and IL-2 enhances the attack power of T cells.

Autotelic Bio CEO, Tae Hun Kim mentioned, “Through this agreement with Clinigen Group, we can now endeavor to successfully complete our Phase 1b clinical trial of ATB-301 looking at this combination and its potential anticancer effects”.